Nitazoxanide in Treatment of Helicobacter priori: A Clinical and In Vitro Study

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 12, 2003, Pages 3780-3783

  Guttner, Yvonne ^a   Windsor, Helen M ^a   Viiala, Charlie H ^a   Dusci, Leon ^b   Marshall, Barry J ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b PathCentre ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NITAZOXANIDE; TIZOXANIDE;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG SALIVA LEVEL; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DYSPEPSIA; ERADICATION THERAPY; FEMALE; FOLLOW UP; HEADACHE; HELICOBACTER PYLORI; HUMAN; IN VITRO STUDY; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MYALGIA; NAUSEA; PATIENT MONITORING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RASH; SKIN DISCOLORATION; TASTE DISORDER; TREATMENT OUTCOME; UREA BREATH TEST; VERTIGO; VOMITING;

EID: 0344875083     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.12.3780-3783.2003     Document Type: Article

References (23)

1. Arya, S. C. 2002. Nitazoxanide as a broad-spectrum antiparasitic agent. J. Infect. Dis. 185:1692.
2. Axon, A. T. R. 2000. Treatment of Helicobacter pylori: an overview. Aliment. Pharmacol. Ther. 14(Suppl. 3):1-6.
3. Bicart-Sée, A., P. Massip, M. D. Linas, and A. Datry. 2000. Successful treatment with nitazoxanide of Enterocytozoon bieneusi microsporidiosis in a patient with AIDS. Antimicrob. Agents Chemother. 44:167-168.
4. Broekhuysen, J., A. Stockis, R. L. Lins, J. De Graeve, and J. F. Rossignol. 2000. Nitazoxanide: pharmacokinetics and metabolism in man. Int. J. Clin. Pharmacol. Ther. 38:387-394.
5. Doumbo, O., J. F. Rossignol, E. Pichard, H. A. Traore, T. M. Dembele, M. Diakite, F. Traore, and D. A. Diallo. 1997. Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am. J. Trop. Med. Hyg. 56:637-639.
6. Dubreuil, L., I. Houcke, Y. Mouton, and J. F. Rossignol. 1996. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob. Agents Chemother. 40:2266-2270.
7. Gargala, G., A. Delaunay, X. Li, P. Brasseur, L. Favennec, and J. J. Ballet. 2000. Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells. J. Antimicrob. Chemother. 46:57-60.
8. Gilles, H. M., and P. S. Hoffman. 2002. Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends Parasitol. 18:95-97.
9. Laheij, R. J., L. G. Rossum, J. B. Jansen, H. Straatman, and A. L. Verbeek. 1999. Evaluation of treatment regimens to cure Helicobacter pylori infection-a meta-analysis. Aliment. Pharmacol. Ther. 13:857-864.
10. McVay, C. S., and R. D. Rolfe. 2000. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob. Agents Chemother. 44:2254-2258.
11. Megraud, F., A. Occhialini, and J. F. Rossignol. 1998. Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole. Antimicrob. Agents Chemother. 42:2836-2840.
12. Ortiz, J. J., A. Ayoub, G. Gargala, N. L. Chegne, and L. Favennec. 2001. Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from northern Peru. Aliment. Pharmacol. Ther. 15:1409-1415.
13. Romero Cabello, R., L. R. Guerrero, M. R. Munoz Garcia, and A. Geyne Cruz. 1997. Nitazoxanide for the treatment of intestinal protozoan and helminthic infections in Mexico. Trans. R. Soc. Trop. Med. Hyg. 91:701-703.
14. Rossignol, J. F., A. Ayoub, and M. S. Ayers. 2001. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. J. Infect. Dis. 184:103-106.
15. Rossignol, J. F., A. Ayoub, and M. S. Ayers. 2001. Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double blind, placebo-controlled study of nitazoxanide. J. Infect. Dis. 184:381-384.
16. Samuels, A. L., H. M. Windsor, G. Y. Ho, L. D. Goodwin, and B. J. Marshall. 2000. Culture of Helicobacter pylori from a gastric string may be an alternative to endoscopic biopsy. J. Clin. Microbiol. 38:2438-2439.
17. Sisson, G., A. Goodwin, A. Raudonikiene, N. J. Hughes, A. K. Mukhopadhyay, D. E. Berg, and P. S. Hoffman. 2002. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori. Antimicrob. Agents Chemother. 46:2116-2123.
18. Stockis, A., X. Deroubaix, R. Lins, B. Jeanbaptiste, P. Calderon, and J. F. Rossignol. 1996. Pharmacokinetics of nitazoxanide after single oral dose administration in 6 healthy volunteers. Int. J. Clin. Pharmacol. Ther. 34:349-351.
19. Stockis, A., A. M. Allemon, S. De Bruyn, and C. Gengler. 2002. Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses. Int. J. Clin. Pharmacol. Ther. 40:213-220.
20. Stockis, A., S. De Bruyn, C. Gengler, and D. Rosillon. 2002. Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1 g b.i.d. Int. J. Clin. Pharmacol. Ther. 40:221-227.
21. Theodos, C. M., J. K. Griffiths, J. D'Onfro, A. Fairfield, and S. Tzipori. 1998. Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrob. Agents Chemother. 42:1959-1965.
22. Windsor, H. M., G. Y. Ho, and B. J. Marshall. 1999. Successful recovery of H. pylori from rapid urease tests (CLO tests). Am. J. Gastroenterol. 94:3181-3183.
23. Yamamoto, Y., A. Hakki, H. Friedman, S. Okubo, T. Shimamura, P. S Hoffman, and J. F. Rossignol. 1999. Nitazoxanide, a nitrothiazolide anti-parasitic drug, is an anti-Helicobacter pylori agent with anti-vacuolating toxin activity. Chemotherapy (Basel) 45:303-312.